Brokers Issue Forecasts for I-Mab’s Q3 Earnings (NASDAQ:NBP)

I-Mab (NASDAQ:NBP) – Research analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for I-Mab in a report released on Thursday, August 20th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.08) per share for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for I-Mab’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for I-Mab’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.30) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.70) EPS, FY2029 earnings at ($0.59) EPS and FY2030 earnings at ($0.47) EPS.

Several other equities analysts have also recently weighed in on the stock. Wall Street Zen raised shares of I-Mab from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised shares of I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, I-Mab currently has a consensus rating of “Hold” and an average price target of $9.00.

I-Mab Stock Up 2.1%

Shares of I-Mab stock opened at $1.93 on Monday. The stock has a market cap of $223.20 million, a P/E ratio of -5.36 and a beta of 1.47. I-Mab has a 12-month low of $1.46 and a 12-month high of $6.79. The business’s 50 day moving average is $1.80 and its 200-day moving average is $2.26.

I-Mab (NASDAQ:NBP) last posted its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter.

Hedge Funds Weigh In On I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group acquired a new stake in I-Mab (NASDAQ:NBP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is owned by hedge funds and other institutional investors.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.